Randomized trial · people

Survodutide: 12.2% weight loss and less liver fat at 48 weeks

Checked against the paper Randomized trialPublished by PepVault

The takeaway

This phase 3 trial adds evidence that survodutide lowered liver fat and body weight more than placebo over 48 weeks in adults with obesity and at-risk fatty liver disease, with mostly gastrointestinal side effects.

Kind
Randomized trial
Studied in
People
Number studied
216
Published
2026
Journal
Nat Med

What they tested

The team tested whether survodutide lowers liver fat and body weight more than placebo in adults with obesity and at-risk fatty liver disease.

How the study was done

A phase 3 randomized, double-blind, placebo-controlled trial in 216 adults with obesity and at-risk MASLD (fatty liver disease tied to metabolic problems, with signs of liver inflammation or scarring). Participants got weekly injections of survodutide 6.0 mg or placebo (a dummy shot) in a 2:1 ratio for 48 weeks, at sites in the United States and Spain.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking survodutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At 48 weeks, 84.2% of people on survodutide had at least a 30% drop in liver fat on MRI-PDFF (an MRI measure of liver fat), compared with 24.3% on placebo, using the trial's efficacy estimand; with the treatment regimen estimand, the figures were 68.5% versus 28.6%. Body weight changed by -12.2% with survodutide and -1.0% with placebo by the first method, and by -8.7% versus -1.4% by the second. All of these differences had P < 0.0001. The most common side effects were gastrointestinal, often during dose increases, and mostly mild to moderate.

What it doesn’t show

The trial lasted only 48 weeks and enrolled people only in the United States and Spain. It tested a single dose, 6.0 mg, against placebo.

The paper

Kaplan et al. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2026.

The compound

More studies on Survodutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking survodutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo